Prosidion's future up in the air as Astellas begins assessing options
This article was originally published in Scrip
Executive Summary
Astellas has begun considering strategic options for the future of its UK R&D subsidiary Prosidion, which it acquired last year as part of the purchase of OSI Pharmaceuticals but now apparently considers surplus to its core interests.